PharmaResearch acquires TuringBio for digital therapeutics
PharmaResearch Co., a South Korean company specializing in regenerative medicine, announced on Wednesday that it acquired TuringBio, an AI-based dig...
Investors dump Korean biotech HLB stocks on FDA rejection
HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...
Korean biotech Xcell Therapeutics eyes June IPO
South Korean biotech Xcell Therapeutics Inc., a developer of chemically defined media for in vitro cell culture, is aiming for a junior bourse Kosda...
Samsung invests in BrickBio in US
Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugates (ADC) and gene therapy technol...
HLB gets global rights to Chinese liver cancer drug
South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...
HLB signs with Japan's OSCL for exclusive supply of C-Trelin ingredient
South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has entered into a business agreement with Japan's Osaka Syn...
Celltrion to develop Humira biosimilar oral medication with US firm
South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...
HLB submits new drug application to FDA for Rivoceranib liver cancer drug
HLB Co. announced on May 17 that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Rivo...
Welt gets second digital therapeutic device approval in S. Korea
South Korea's Ministry of Food and Drug Safety announced on Wednesday that it has approved the cognitive therapy software "WELT-I" developed by We...
Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer
South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...
HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US
South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...
HLB Cell develops organoid biomaterial based on human normal cells
HLB Cell, a subsidiary of HLB Life Science Co., which specializes in the development of cell therapy products, announced on April 4 that it succeede...
GC Biopharma to develop mRNA flu vaccine with Canadian pharma
South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...
AIMMED’s Somzz ushers in digital therapeutic device market in Korea
South Korea’s health and drug safety authority has cleared Somzz to treat patients with sleep disorders, a dynamic move that is expected to vi...
Hanall Biopharma invests in Interon Labs for brain disease treatments
South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments fo...
HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China
South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., ...
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Korea’s big bio startups to launch $39 mn investment fund
South Korea’s four leading biotech firms plan to launch an investment fund of up to 50 billion won ($39 million) to support smaller domestic b...
HLB Therapeutics signs contract for COVID vaccine distribution rights
South Korea's pharmaceutical firm HLB Therapeutics Co. said on Monday that it has signed an agreement with the Korea Disease Control and Prevention ...
New drug developer Onconic Therapeutics raises $20 mn in Series B
South Korean drug developer Onconic Therapeutics, announced on Friday that it raised 26 billion won ($19.9 million) in Series B funding, with cumula...
MDimune signs research agreement with Australian National University
MDimune, a South Korean biotech company, said on Wednesday that it had signed an agreement with the Clear Vision Research (CVR) Lab, a research grou...
SK Discovery to control affiliates’ entire biotechnology business
SK Discovery Co., an intermediate holding company of South Korea’s third-largest conglomerate SK Group, will take charge of the entire biotech...
Samsung Biologics to double CDMO capacity with new plants worth $5.3 bn
Samsung Biologics Co., the world’s largest contract drugmaker, plans to double its manufacturing capacity by building four additional plants w...
Korean biotech firms fold COVID-19 therapeutics development businesses
A string of South Korean pharmaceutical and biotech companies are waving the white flag when it comes to developing COVID-19 treatments. As the...
KT, Hanmi-invested therapeutics maker Digital Pharm launched
Digital Pharm, jointly invested in by KT Corp. and Hanmi Pharmaceutical Co., held an official inauguration ceremony last week, the company announced...
SK invests in US digital healthcare firm Cala Health
South Korea's SK Biopharmaceuticals Co. has dipped its toes into the rapidly growing digital healthcare market by investing in Cala Health, a US-bas...
Samsung buys $2.3 bn Bioepis stake from Biogen to end partnership
Samsung Biologics Co. is acquiring a nearly 50% stake in a biosimilar joint venture with Biogen Inc. from the US biotechnology company for $2.3 bill...
Korean pharma joins global race in RNA therapeutics development
The field of ribonucleic acid (RNA) therapeutics, once considered an unexplored area, is now the most coveted sector in the global biotech industry....
Celltrion, Mirae to take largest stake in UK biotech firm
South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...
